Individuals with malignant pleural effusion undergoing talc pleurodesis have comparable outcomes regardless of how the talc is delivered, shows a phase 3 trial reported in JAMA.
W Fraser Symmans takes us through their patient-level pooled analysis identifying residual cancer burden as a predictive factor for recurrence across all breast cancer subtypes, and its subsequent potential to inform treatment choice (6:49).
Joaquín Gavilá highlights the phase 2 SOLTI-1402/CORALLEEN trial findings demonstrating comparable clinical benefit and reduced toxicity of combined neoadjuvant endocrine and CDK 4/6 inhibitor therapy versus chemotherapy in patients with high-risk luminal B breast cancer (2:44).
Icro Meattini shares long-term findings from their phase 3 trial pitting accelerated partial breast against whole breast irradiation in women with early-stage breast cancer (1:39).
Gerardo Umanzor discusses phase 3 findings showing improved survival and reduced neuropathy with orally administered versus intravenous paclitaxel in patients with metastatic breast cancer (3:12).
Rowan Chlebowski outlines the findings from the Women's Health Initiative trials investigating the effect of oestrogen, either alone or with progestin, on breast cancer risk, and puts them in context of recent opposing data (4:10).